ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 10% YoY overall; Biosimilars 16%, Generics 21%. |
|---|---|
| Margins | EBITDA margin at 21%; Generics margin improved 250bps QoQ. |
| Demand visibility | Strong visibility in North America; meaningful improvement expected in H2. |
| Management confidence | High for H2 FY27 driven by new launches. |
Growth
Biosimilars revenue grew 16% YoY; Generics up 21%. Services (Syngene) declined 16% due to lower client offtake.
Outlook
Stronger H2 FY27 expected for Biosimilars; return to sustainable growth for Services guided from FY28.
Risks
Services segment facing transition year headwinds and forex hedge losses; global pricing pressure in biosimilars.
Last quarter's promises, checked
Delivered
- Interest savings guide INR 75Cr/qtr → delivered INR 75Cr/qtr (= BEAT)
- Biosimilars H1 FY27 growth → delivered 16% YoY (= BEAT)
- Generics margin improvement → delivered 250bps QoQ (= BEAT)
Partly delivered
- Net debt reduction to $1.1B → delivered $1.1B but remains working capital sensitive (= PARTIAL)
Missed
- Syngene stable performance → delivered -16% revenue (= MISS)
Investor Presentation filed with NSE, NSE: BIOCON. Summary written with AI assistance from the document.
Biocon Ltd: key numbers
- Share price
- ₹368.05
- Market cap
- ₹59,981 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 132.7×Sector 43.8×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Earnings Call Transcript: Key Takeaways
Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.
Biocon Management Change
Biocon's board recorded the resignation of Chief Technology Officer Mandar Ghatnekar, effective 31 December 2026. Mukesh Rathi is appointed CTO, effective 1 January 2027.
Biocon Other Announcement
Biocon Limited informed the Exchange of shareholder communications regarding the withholding of FY 2025-26 final dividends for missing mandatory KYC and bank details.
Biocon Investor Presentation: Key Takeaways
Q2 FY27 revenue from operations ₹4,389 Cr (+2% YoY), EBITDA ₹865 Cr (20% margin vs 22%), reported PAT ₹41 Cr (−52% YoY). Management expects a stronger H2.
Biocon Results Update
Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.
Biocon Q2 FY27 Results: Net Profit ₹56.7 Cr, Down 57.3% YoY
Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.7 Cr · -57.3% YoY